886366-17-2

Basic information

• Product Name: (5-BROMO-PYRIMIDIN-2-YL)-CYCLOHEXYL-AMINE
• Synonyms: (5-BROMO-PYRIMIDIN-2-YL)-CYCLOHEXYL-AMINE;5-BROMO-N-CYCLOHEXYLPYRIMIDIN-2-AMINE;5-Bromo-2-cyclohexylaminopyrimidine
• CAS NO: 886366-17-2
• Molecular Formula: C₁₀H₁₄BrN₃
• Molecular Weight: 256.14
• Mol File: 886366-17-2.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (5-BROMO-PYRIMIDIN-2-YL)-CYCLOHEXYL-AMINE(CAS DataBase Reference)
• NIST Chemistry Reference: (5-BROMO-PYRIMIDIN-2-YL)-CYCLOHEXYL-AMINE(886366-17-2)
• EPA Substance Registry System: (5-BROMO-PYRIMIDIN-2-YL)-CYCLOHEXYL-AMINE(886366-17-2)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• Hazardous Substances Data: 886366-17-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(5-BROMO-PYRIMIDIN-2-YL)-CYCLOHEXYL-AMINE is used as an intermediate compound for the synthesis of various pharmaceuticals, contributing to the development of potential drug candidates for a range of therapeutic applications. Its unique structure allows for the creation of new molecules with specific biological activities, making it a valuable asset in drug discovery and medicinal chemistry.
Used in Agricultural Industry:
In the agricultural sector, (5-BROMO-PYRIMIDIN-2-YL)-CYCLOHEXYL-AMINE is utilized as an intermediate in the production of agrochemicals, aiding in the development of effective and targeted pest control solutions. Its role in the synthesis of agrochemicals helps to enhance crop protection and contribute to sustainable agricultural practices.
Used as a Research Reagent:
(5-BROMO-PYRIMIDIN-2-YL)-CYCLOHEXYL-AMINE is employed as a research reagent in chemical and medicinal studies, where its versatile chemical properties facilitate investigations into new chemical reactions, synthesis pathways, and the exploration of its potential biological activities. This application supports the advancement of knowledge in chemistry and medicine, fostering innovation in drug and agrochemical development.

Upstream product

• 108-91-8 cyclohexylamine 
• 32779-36-5 5-Bromo-2-chloropyrimidine 

Downstream Products

• 1407999-92-1 C₃₃H₃₈F₃N₉O 
• 1581701-31-6 2-(cyclohexylamino)-N-(2-methyl-5-((4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)carbamoyl)phenyl)pyrimidine-5-carboxamide 
• 1215560-20-5 C₁₁H₁₅N₃O₂ 
• 1581701-24-7 C₁₂H₁₇N₃O₂ 
• 1257628-65-1 3-(2-(2-(cyclohexylamino)pyrimidin-5-yl)ethynyl)-4-methyl-N-(3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl)benzamide 
• 1408000-37-2 N-cyclohexyl-5-ethynylpyrimidin-2-amine 

Relevant articles and documents

Heterocyclic benzoyl amide compounds, medicinal composition and use thereof

The invention discloses heterocyclic benzamide compounds with structural characteristics of formula (1) or pharmaceutically acceptable salts or steric isomers or prodrug molecules thereof. The heterocyclic benzamide compounds as well as pharmaceutically acceptable salts thereof can effectively restrain growth of a plurality of tumor cells, can generate inhibiting effect to proteases such as BCR-ABL, c-Kit and PDGFR, can be used for preparing anti-tumor drugs and can be used for overcoming existing drug (Gleevec)-induced drug resistance.

Design, synthesis, and biological evaluation of 3-(1H-1,2,3-triazol-1-yl) benzamide derivatives as potent pan Bcr-Abl inhibitors including the threonine315←isoleucine315 mutant

A series of 3-(1H-1,2,3-triazol-1-yl)benzamide derivatives were designed and synthesized as new Bcr-Abl inhibitors by using combinational strategies of bioisosteric replacement, scaffold hopping, and conformational constraint. The compounds displayed significant inhibition against a broad spectrum of Bcr-Abl mutants including the gatekeeper T315I and p-loop mutations, which are associated with disease progression in CML. The most potent compounds 6q and 6qo strongly inhibited the kinase activities of Bcr-AblWT and Bcr-AblT315I with IC50 values of 0.60, 0.36 and 1.12, 0.98 nM, respectively. They also potently suppressed the proliferation of K562, KU812 human CML cells, and a panel of murine Ba/F3 cells ectopically expressing either Bcr-AblWT or any of a panel of other Bcr-Abl mutants that have been shown to contribute to clinical acquired resistance, including Bcr-AblT315I, with IC50 values in low nanomolar ranges. These compounds may serve as lead compounds for further development of new Bcr-Abl inhibitors capable of overcoming clinical acquired resistance against imatinib.